SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1084)7/28/2006 11:35:36 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 3661
 
Nice summary for us lately-lazy folk. Thanks.

You'll remember from discussions subsequent to Large Scale visit, that anti-id is an old tale.

The antigen is there. But B cells are DESIGNED to make that antigen hypervariable. Past attempts (largely at Idec, back before they were saved from bankruptcy brink by Genentech) have shown that a successful immunization doesn't lead to prolonged survival.

I don't follow the company either. So, I'll probably be on top of the story AFTER it has been told.

:-)

But I'll be interested in it.



To: tuck who wrote (1084)7/28/2006 11:40:01 AM
From: rkrw  Respond to of 3661
 
Another case of a company showing amazing open label survival data, maybe the expectation was if it held up surely the trial would be stopped?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News